Literature DB >> 24411213

Challenges and recommendations for early identification of metastatic disease in prostate cancer.

E David Crawford1, Nelson N Stone2, Evan Y Yu3, Phillip J Koo4, Stephen J Freedland5, Susan F Slovin6, Leonard G Gomella7, E Roy Berger8, Thomas E Keane9, Paul Sieber10, Neal D Shore11, Daniel P Petrylak12.   

Abstract

Prostate cancer is often associated with metastases to bone and/or soft tissue. The progression to metastatic castrate-resistant prostate cancer is a seminal event in disease progression affecting treatment decisions. A multidisciplinary group was convened to review the currently available imaging guidelines for metastatic disease in prostate cancer and found no consensus on eligibility criteria, type of imaging modality, and the frequency of scanning for detecting metastatic disease. The aim of this review was to present the recommendations from the group to identify optimal strategies for early identification of metastases in patients with prostate cancer.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24411213     DOI： 10.1016/j.urology.2013.10.026

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


  25 in total

Review 1.  Imaging of distant metastases of prostate cancer.

Authors:  Filippo Pesapane; Marcin Czarniecki; Matteo Basilio Suter; Baris Turkbey; Geert Villeirs
Journal:  Med Oncol       Date:  2018-09-14       Impact factor: 3.064

Review 2.  Imaging and evaluation of patients with high-risk prostate cancer.

Authors:  Marc A Bjurlin; Andrew B Rosenkrantz; Luis S Beltran; Roy A Raad; Samir S Taneja
Journal:  Nat Rev Urol       Date:  2015-10-20       Impact factor: 14.432

Review 3.  Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET.

Authors:  Phillip J Koo; Jennifer J Kwak; Sajal Pokharel; Peter L Choyke
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

Review 4.  Molecular mechanisms of curcumin and its semisynthetic analogues in prostate cancer prevention and treatment.

Authors:  Brian C Jordan; Charlotta D Mock; Ramasamy Thilagavathi; Chelliah Selvam
Journal:  Life Sci       Date:  2016-03-24       Impact factor: 5.037

Review 5.  Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management.

Authors:  Francois Rozet; Thierry Roumeguère; Martin Spahn; Dirk Beyersdorff; Peter Hammerer
Journal:  World J Urol       Date:  2016-03-17       Impact factor: 4.226

6.  Astragaloside attenuates the progression of prostate cancer cells through endoplasmic reticulum stress pathways.

Authors:  Bo Tan; Renfeng Jia; Gang Wang; Jinhui Yang
Journal:  Oncol Lett       Date:  2018-07-04       Impact factor: 2.967

7.  Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.

Authors:  Lauren E Howard; Daniel M Moreira; Amanda De Hoedt; William J Aronson; Christopher J Kane; Christopher L Amling; Matthew R Cooperberg; Martha K Terris; Stephen J Freedland
Journal:  BJU Int       Date:  2017-04-30       Impact factor: 5.588

Review 8.  The biology of castration-resistant prostate cancer.

Authors:  Fei Lian; Nitya V Sharma; Josue D Moran; Carlos S Moreno
Journal:  Curr Probl Cancer       Date:  2014-11-25       Impact factor: 3.187

9.  Baseline 18F-Fluorocholine PET/CT and bone scan in the outcome prediction of patients treated with radium 223 dichloride.

Authors:  A M García Vicente; B González García; M Amo-Salas; I García Carbonero; J Cassinello Espinosa; J L Gómez-Aldaraví Gutierrez; L Suarez Hinojosa; Á Soriano Castrejón
Journal:  Clin Transl Oncol       Date:  2018-07-13       Impact factor: 3.405

10.  Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer.

Authors:  Stephen J Freedland; Lauren E Howard; Brian T Hanyok; Vishnu K Kadiyala; Jameson Y Kuang; Colette A Whitney; Floyd R Wilks; Christopher J Kane; Martha K Terris; Christopher L Amling; Matthew R Cooperberg; William J Aronson; Daniel M Moreira
Journal:  BJU Int       Date:  2016-02-08       Impact factor: 5.588
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.